NewLimit's $435M Raise and Factory Capital's Women's Health Bet Signal a Clinical Turn in Longevity
NewLimit has closed the largest single raise in longevity biotech, securing $435M to advance its first epigenetic-reprogramming compound into clinical trials by 2027. For advisors selling SHA Wellness, Lanserhof, and Clinique La Prairie, this reshapes the credibility conversation: high-net-worth clients will increasingly arrive asking how a hospitality longevity program differs from what is now entering pharma trials. Advisors who can articulate that distinction — and price accordingly — will hold authority.
Separately, Sydney-based Factory Capital has committed $18M to physical clinical infrastructure for perimenopause and women's midlife health — brick-and-mortar facilities, not apps. Institutional capital moving into specialist women's clinical space typically surfaces new programming within 12–24 months. Advisors with strong women's wellness portfolios — Miraval, Canyon Ranch, Ananda in the Himalayas — should watch for clinical partnership announcements from established destination spas seeking to align with this incoming supply.
Signos's FDA-Cleared OTC Glucose Monitor Goes Retail — and Into Your Clients' Bags Before Arrival
Signos, backed by Google Ventures and Dexcom, has launched its FDA-cleared continuous glucose monitor for weight management over the counter on Dexcom's Stelo.com. The shift from clinical-exclusive to consumer retail is consequential: clients will increasingly arrive at Mayrlife, SHA, Palace Merano, and Lanserhof carrying weeks of self-collected metabolic data. Properties that integrate consumer CGM into pre-arrival intake protocols become a material differentiation point — and a stronger justification for premium program pricing against self-managed protocols.
Advisors should proactively probe whether booked programs accept consumer-device data in health questionnaires. Those that do provide a ready answer to the client question that is only going to grow: why pay for a medically supervised metabolic program when I can track my own glucose at home?
Lanesborough Club & Spa Opens London's First Dedicated IV-Infusion Suite With NAD+ and Jet Lag Drip
The Lanesborough has launched a dedicated IV-infusion suite in partnership with functional medicine specialist Dr. Galyna Selezneva, adding The Detox Drip, The Jet Lag Drip, and Advanced NAD+ therapies to one of London's most established five-star hotel spa facilities. Previously strong on fitness and aesthetics, the property now carries a clinical wellness credential that directly serves transatlantic routing.
For advisors building Gulf-to-Europe or New York–London itineraries, the Jet Lag Drip is a concrete, bookable recovery stop on arrival — no separate clinic visit required. Both advance-book and walk-in availability make it a practical pre-program reset for clients continuing to European destination spas or longevity clinics in Switzerland, Spain, or Bavaria. The IV suite positions the Lanesborough squarely within the luxury clinical wellness segment rather than standard hotel spa — a meaningful step-up in how the property can be sold.
Wellhub: 90% of Employees Burned Out, Corporate Wellness Check-Ins Up 10× in Three Years
Wellhub's 2026 State of Work-Life Wellness Report, released ahead of the SHRM annual conference — attended by the world's largest concentration of HR decision-makers — places near-universal burnout on the corporate agenda at exactly the moment wellness spending is accelerating. Gen Z, the workforce's fastest-growing cohort, reports the highest burnout levels. Corporate wellness check-ins have risen tenfold over three years.
For advisors with a corporate and executive retreat practice, these figures are a ready-made pitch document: the data now justifies multi-day immersive destination spa buyouts over single-day offsites. The SHRM timing is deliberate — share the Wellhub statistics with HR directors and benefits managers this month, when wellness ROI is front of mind for the decision-makers who authorize retreat budgets. Burnout at 90 percent is not a wellness trend; it is an HR liability, and framing it that way converts a discretionary line item into a business case.